The renin-angiotensin system is activated in acute severe asthma. Angiotensin II causes bronchoconstriction in mild asthmatics and potentiates methacholine-evoked bronchoconstriction both in vitro and in vivo.
Introduction
The renin-angiotensin system is activated in acute severe asthma with elevation of plasma renin and angiotensin II levels (1) . Its active octapeptide hormone angiotensin II, a potent vasoconstrictor, also causes weak bronchoconstriction when administered intravenously to mild asthmatics (l), although it is not known if this effect is receptor mediated in vivo. Angiotensin II can potentiate vagally mediated contraction of rabbit airway smooth muscle via a prejunctional effect on cholinergic nerve terminals (2) and has a postjunctional potentiating effect on sympathetic contraction of rabbit saphenous artery (3) (4) (5) . It also enhances tissue responses to noradrenaline (6).
The present authors have shown previously that subthreshold concentrations of angiotensin II enhance methacholine-induced bronchoconstriction both in vitro and in vivo (7), and endothelin-l-evoked bronchoconstriction of bovine airways in vitro, by a type-l angiotensin II receptor-specific effect (8). The mechanism of this potentiating effect remains obscure but the possible interaction with other spasmogens in the airway exists. Histamine is a potent bronchoconstrictor which is released from mast cells in asthmatic airways and therefore is an important spasmogen and any potential interaction with angiotensin II would be relevant.
Therefore, the current study examined the effect of angiotensin II at subthreshold doses on histamineinduced bronchoconstriction in human airways in vitro and in vivo.
Materials
and Methods
IN VITRO Tissue Collection and Preparation
Macroscopically normal human bronchial tissues (3rd to 6th order) were obtained from patients undergoing thoracotomy for bronchial carcinoma. All patients were smokers but information about pulmonary function was unavailable; none suffered from asthma. Tissues were dissected free of connective tissue and fat, and stored overnight at 40°C in oxygenated Krebs-Henseleit solution of the following composition; NaCl 118.4 mM, KC1 4.7 mM, CaCl, 2.5 mM, MgSO, 1.2 mM, NaHCO, 24.9 mM, KH,PO, 1.2 mM and glucose 11.1 mM. Published data has shown that overnight storage of this tissue does not alter its reactivity (9).
Measurement of Contractile Responses
Contractile responses were measured from rings of human bronchi (3-5 mm) in vertical organ baths (10 ml) at 37 f 0.5"C in oxygenated (95% O,, 5% CO,) Krebs-Henseleit solution. Tension (2 g) was applied via two platinum wires into the lumen. One wire was anchored and the other attached to a force displacement transducer (Grass FT03T). Tissues were allowed to equilibrate for 2 h during which time applied tension was readjusted to the initial level.
Cumulative concentration-response curves were constructed to angiotensin II to ascertain the threshold for contraction to this hormone. Angiotensin II produced small (co.25 g maximum), concentration-dependent contractions of human bronchi, with the threshold for contraction occurring between 10 -7 M and 10 -6 M ( Fig. 1 ). This compared with the maximum contraction of mean (SEM) 1.45 (0.28) g with 3 x 10 -4 M histamine. 1. Cumulative concentration-response curve to angiotensin II at 10 -a M to 10 -5 M showing the contractile response as milligram tension generated. Number of observations (n) = 4.
In subsequent experiments, cumulative concentrationresponse curves were constructed to histamine (10 -9-3 x 10 -4 M) in the presence and absence of angiotensin II (10 -7 M, 3 X 10 -7 M and 10 -6 M). Drugs were added directly to the organ bath and angiotensin II was added 15 min before histamine concentration-response curves.
IN VW0

Patients
Eight mild asthmatic volunteers (five males) were recruited with mean (range) age 41 (27-69) years and baseline FEV, 88 (78-106) % of predicted. Bronchial hyper-responsiveness to inhaled histamine was demonstrated by challenge testing according to the method of Cockcroft et al. (10) . Individuals found to be hypertensive, pregnant or taking antihistamines, diuretics or angiotensin-converting enyzme inhibitors were excluded. Two subjects were current and one was a former smoker. Seven subjects were taking inhaled salbutamol as required, four were taking additional low dose (<10OO,~g daily) inhaled beclomethasone dipropionate, one was taking additional salmeterol and one was on no treatment (Table 1 ). Prior to each study day, subjects were instructed to withhold short-acting P-agonists for 8 h and longacting P-agonists for 12 h but inhaled corticosteroids were continued unchanged.
Ethical approval for the study was obtained from the Glasgow West Ethical Committee and written, informed consent was obtained from the study volunteers prior to commencing the study. S, salbutamol (pm); BDP, beclomethasone dipropionate (< 1000 ,ug day -'); Sm, salmeterol; *geometric mean.
Study Pvotocol Measwements
The study design was randomized, double-blind and placebo controlled. The subjects attended the laboratory on four separate occasions; initially for a screening visit comprising a physical examination followed by a histamine bronchial provocation test. This was performed using a Wright's nebulizer, calibrated to give an output of 0.12 ml min-' at a flow rate of 8 lmin-' air, to define the concentration required to cause a 20% fall in FEV, from baseline (the PC,, histamine). On the three subsequent visits, an intravenous cannula (Venflon, Viggio AB, Helsinborg, Sweden) was inserted into a vein on each forearm; after 30 min rest, a blood sample was extracted to measure baseline plasma renin and angiotensin II levels. Baseline spirometry, pulse, blood pressure and pulse oximetry were measured then an intravenous infusion commenced via a 50-ml syringe driver (Perfusor Secura E, B.B. Braun, Melsunger AG, Germany). Subjects received either placebo (5% dextrose) or angiotensin II at subthreshold doses for bronchoconstriction of 1 or 2 ng kg -' min -' over 1 h. After 30 min, steady state was deemed to have been reached and a further blood sample was taken from the arm opposite to the infusion and the FEV, repeated. A histamine bronchial provocation test was then performed and the PC,, noted. At the completion of the test, a further blood sample was taken, then the bronchoconstriction was reversed with nebulized salbutamol (Ventolin, Allen and Hanburys, U.K.). Throughout the study pulse, blood pressure and oxygen saturation were monitored at 15-min intervals.
FEV,. Spirometry was measured using a dry wedge spirometer (Vitalograph Model S, Buckinghamshire, U.K.), the best of three measurements being taken at each time point.
Pulse and Blood Pressure. A semi-automatic sphygomomanometer (Dinamap, 1846SX Vital Signs Monitor, Critikon, Florida, U.S.A.) was used to measure pulse and blood pressure from the opposite arm to the infusion at each time point.
Oxygen
Saturation. Oxygen saturation was measured by transcutaneous pulse oximetry (Oscaroxy Pulse Oximeter, Datex, Helsinki, Finland) at each time point.
Histamine Bronchial Provocation Test. Baseline spirometry was measured then repeated after a 2-min inhalation of 0.9% saline, administered via a Wright's nebulizer driven by compressed air, calibrated to give an output of 0.12 ml min -' at a flow rate of 8 litres min -'. Doubling doses of histamine were subsequently administered starting with a dose of 0.0625 mg ml -'. The FEV, was measured at 30, 90 and 180 s following each inhalation until a 20% fall was achieved. The histamine concentration causing a 20% fall in FEV, was calculated by linear regression and taken as the PC,,.
Angiotensin II Assay. Blood samples were collected into iced lo-ml plastic tubes containing EDTA and 0-phenanthroline inhibitor. They were placed on ice until separation by centrifugation at 3000 g for 15 min, then the plasma was frozen at -20°C until analysis. The assay for angiotensin II is a modified radioimmunoassay which uses C,, cartridges (SepPak; Waters, Milford, MA, U.S.A.) to extract angiotensin II from plasma (11). The intra-assay coefficient of variation is 6.4% and inter-assay variation 10%. The reference range for the authors' laboratory is 3-12 pg ml-' (2.9-l 1.5 x lop9 M).
Renin Assay. Blood samples for renin were collected in 5-ml glass tubes containing EDTA then placed on ice and frozen at -20°C until analysis. Plasma renin concentration was measured using an antibody trapping technique (12). The intra-assay coefficient of variation is 5.5% and the inter-assay variation 11% (13). The reference range for the authors' laboratory is 9-50 ,LLU ml ~ '.
Drugs. The drugs used were histamine (Fluka Chemicals, Gillingham, U.K. for in vivo studies: Sigma Chemicals, Poole, U.K. for in vitro studies) and angiotensin II (Sigma Chemicals, U.K.). For the in vitro studies, both histamine and angiotensin II were prepared as a stock solution in distilled water, then serial dilutions were prepared in KrebsHenseleit solution. For in vivo studies, serial dilutions of histamine were prepared in phosphate-buffered saline ranging from 0.0625 to 8.0 mg ml-'. Angiotensin II was prepared in 5% dextrose under sterile conditions. Statistical Analysis. Statistical significance was determined by two-way analysis of variance (ANOVA) for in vitro studies and one-way ANOVA for in vivo studies with a probability level of PcO.05 considered significant. Histamine PC,, values were transformed logarithmically prior to statistical analysis.
Results
IN VITRO STUDIES
Pre-incubation with angiotensin II (10 -7 M) evoked contraction in only two of the six tissues and in both cases the contraction was less than 0.1 g compared with the control maximum contraction of mean 1.45 (SEM 0.28) g with histamine (3 x 10p4~). No significant enhancement (P>O.O5) of histamineevoked contractions (10 -9 ~-3 x 10 -4 M) was seen in any of the tissues following pre-incubation with angiotensin II at 10p7~, 3 x 10p7~ and 10K6~ (Fig. 2) . 
IN VIL'O STUDIES
On each of the three study days, there was no significant difference between baseline pulse, blood pressure, oxygen saturation, FEV,, plasma renin and plasma angiotensin II measurements (Table 2 ). Prior to histamine challenge and during the infusion, there was no significant change in FEV, noted from baseline values on each study day; mean (SEM) change in FEV, (1) from baseline: placebo -0.08 (0.05), angiotensin II 1 ng kg-' min-' -0.12 (0.04), angiotensin II 2 ng kg -' min -' -0.08 (0.04).
Following histamine bronchial provocation testing on each study day, there was no significant difference in histamine PC,, [geometric mean (range)] between screening [3.48 (1.26-7.75) mg ml -', placebo [2.67 (0.89-9.57), mg ml -', angiotensin II 1 ngkg-1 min-' [2.45 (0.42-6 .97) mg ml -'1 and angiotensin II 2 ng kg-' min-' [3.09 (0.88-10.78) mg ml -'1 study days (Fig. 3) .
A significant rise (PcO.05) in both systolic and diastolic blood pressure occurred following infusion of angiotensin II 1 ng kg -' min -' and 2ng kg-' min-1 compared to placebo [systolic BP mean (SEM) mmHg 121.4 (4.57), 139.4 (6.72) and 140.5 (5.84), and diastolic BP mean (SEM) mmHg 72.0 (2.40), 81.4 (2.54) and 82.88 (2.43) on placebo, angiotensin II 1 ng kg -' min -' and angiotensin II 2ngkg-lmin-' study days, respectively]. However, Results are expressed as means (SEM) . No significant difference was found for any of the above parameters between study days.
FIG . 3 . The PC,, histamine (mg ml -') on the screening day, following placebo infusion and following infusion of angiotensin II 1 ng kg -' min -' and2ngkgg'min-'. Angiotensin II had no effect on the PC,, histamine.
there was no statistically significant difference in either systolic or diastolic blood pressure following histamine challenge on each study day.
No significant changes in pulse rate or oxygen saturation were noted throughout each study day.
Plasma angiotensin II was measured at baseline, steady state (30 min into the infusion) and following completion of the infusion on each study day. On the placebo day, angiotensin II levels remained unchanged; mean (SEM) [ (Fig. 4) .
No adverse effects were reported by the subjects on any of the study days.
Discussion
The results of this study show that angiotensin II does not affect histamine-induced bronchoconstriction in human bronchi either in vitro or in vivo. 4. Plasma angiotensin II levels (pg ml ~ ') measured before, during the infusion and following histamine challenge testing on each study day. *Significant difference from placebo and angiotensin II 2 ng kg-' min-' PcO.05. **Significant difference from placebo and angiotensin II 1 ng kg -' min -' PcO.05. (1) . Therefore, the levels achieved by the infusion of angiotensin II are physiologically relevant. The rise in systolic and diastolic blood pressure during the 1 and 2 ng kg ~ ' min -' angiotensin II infusions confirms its physiological effect. The plasma levels of angiotensin II measured during this study were similar to those found in the previous study by Millar et al. (7), where angiotensin II potentiated methacholine-induced bronchoconstriction.
As there was no significant effect on spirometry following 30 min of the infusion on each study day, it can be concluded that the dose of angiotensin II administered did not cause bronchoconstriction directly.
The reason for angiotensin II potentiating methacholine-induced bronchoconstriction (7) but not histamine-induced bronchoconstriction is undoubtedly complex and may be multi-factorial.
The two studies have heterogeneous groups of subjects although four subjects took part in both studies. The current study group were older [mean (SD) age 41 (5.3) years compared to 27 (8) years in the study by Millar et al. (7)], but both groups were mild asthmatics with mean (SD) FEV, 88 (11) % predicted in the current study and 82 (9) % predicted in the study by Millar et al. (7) . Bronchial reactivity during placebo infusion was similar in both groups with geometric mean (range) PC,, histamine 2.67 (0.89-9.57) mg ml -' in the current study and PC,, methacholine 3.09 (1.15-6 .0) mg ml -' in the study by Millar et al. (7) . Therefore, it is unlikely that variation in patient selection between these two studies has accounted for the different effect of angiotensin II on histamine-and methacholine-induced bronchoconstriction in vivo.
It is possible that, in asthmatics with greater bronchial reactivity the effect of angiotensin II on histamine-induced bronchoconstriction may be different due to more local inflammation, the presence of higher levels of mediators or a greater volume of airway smooth muscle. However, it is established that in mild asthmatics angiotensin II can potentiate the effect of methacholine, thus it appears that there is a fundamental difference between the interaction of angiotensin II with methacholine and histamine.
The lack of interaction between angiotensin II and histamine in the human airway could be explained by the absence of functional angiotensin II receptors in the bronchi. However, although no direct evidence exists demonstrating tissue-specific angiotensin II receptors in the lungs, Curnow et al. (14) have extracted type-l angiotensin II (AT,) receptor mRNA from human lung tissue. Both type-1 (15) and type-2 (16) angiotensin II receptor mRNA has also been identified in foetal rat lung.
Studies on bronchial reactivity in vitro in bovine bronchial rings have shown an AT, receptormediated potentiating effect of angiotensin II on endothelin-l-evoked bronchoconstriction (8). Although the mild bronchoconstrictor effect of angiotensin II on asthmatic airways in vivo (1) and its potentiating effect on methacholine-induced bronchoconstriction on human bronchi both in vitro and in vivo (7) have not been proven to be receptor-specific phenomena, it is likely that functional angiotensin II receptors do exist in the human airway.
The reason for the lack of potentiating effect of angiotensin II in relation to histamine may relate to differing second messenger intracellular pathways and varied cross-talk between pathways. The effect of angiotensin II on intracellular pathways in airway smooth muscle remains to be characterized. However, in vascular tissue, the type-l angiotensin II receptor is coupled to a G-protein activating phospholipase-C and liberating diacylglycerol (DAG) and inositol triphosphate (IP,), resulting in a rise in intracellular calcium concentration (17). In some tissues, the angiotensin II receptor is also coupled to an inhibitory G-protein which inhibits adenylate cyclase (18).
Histamine exerts its effects on airway smooth muscle via the Hi receptor which is also coupled to a G-protein activating phospholipase C and liberating DAG and IP, (19) . The increase in IP, is inhibited by cyclic adenosine-monophosphate (CAMP), attenuating the histamine-induced increase in intracellular calcium in canine airway smooth muscle (19) .
Cholinergic muscarine receptors in the airways are also coupled to membrane phospholipid hydrolysis to form IP, but this occurs by a different pathway which is insensitive to CAMP (19).
Therefore, cross-talk at the second messenger level between angiotensin II intracellular pathways and histamine and acetyl choline/methacholine second messenger pathways could have different end results.
The final site of potential interaction is at the receptor level itself. Angiotensin II uncovers previously silent a2-adrenoceptors in the rabbit distal saphenous artery (5) and if a similar interaction occurred between receptors for different spasmogens in airway smooth muscle this could lead to potentiation.
In conclusion, the role of the renin-angiotensin system in asthma is still incompletely understood. It seems that angiotensin II interacts diversely with different bronchoconstrictors potentiating the effects of methacholine and endothelin-1 but not histamine in the airway.
